期刊文献+

高效毛细管电泳法测定血浆中兰索拉唑对映体浓度 被引量:1

The application of HPCE on the determination of two enantiomers of lansoprazole in human plasma
在线阅读 下载PDF
导出
摘要 目的建立测定血浆中兰索拉唑对映体浓度的高效毛细管电泳分析方法,并用于兰索拉唑在人体内立体选择性药代动力学研究。方法用乙醚作提取溶剂提取血浆中兰索拉唑。采用高效毛细管电泳法测定6名健康男性受试者经口给予兰索拉唑片后不同时刻血浆中药物对映体浓度,绘制血药浓度-时间曲线,并计算主要药动学参数。结果 S—与R—兰索拉唑对映体的主要药动学参数如下:ρmax分别为(0.538±0.039)mg.L-1和(1.050±0.250)mg.L-1,tmax为(1.8±0.7)h和(1.8±0.7)h,t1/2分别为(1.6±0.7)h和(2.7±1.0)h,用梯形法计算,AUC0-t分别为(1.49±0.36)mg.h.L-1和(4.35±1.52)mg.h.L-1。结论兰索拉唑两对映体在人体内的代谢过程具有立体选择性。 Objective To establish a method of capillary electrophoresis for the determination of lansoprazole in human plasma,and study the enantioselectivity of lansoprazole.Methods Human plasma was extracted using ether.The concentration of lansoprazole enantiomers in plasma was determined by HPCE after oral administrated of rac-lansoprazole by six healthy volunteers,then the concentration-time curves were plotted and the main pharmacokinetic parameters were calculated,respectively.Results The main pharmacokinetic parameters of S-lansoprazole and R-lansoprazole were as follows:ρmax were(0.538±0.039)mg · L-1 and(1.050±0.250)mg · L-1,tmax were(1.8±0.7)h and(1.8±0.7)h,t1/2 were(1.6±0.7)h and(2.7±1.0)h,AUC0-t were(1.49±0.36)mg · h · L-1 and(4.35±1.52)mg · h · L-1,AUC0-∞ were(1.67±0.44)mg · h · L-1 and(5.02±1.90)mg · h · L-1,respectively.Conclusions The metabolic process of the two enantiomers of lansoprazole is enantioselective.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2012年第7期535-540,共6页 Journal of Shenyang Pharmaceutical University
关键词 兰索拉唑 高效毛细管电泳 手性分离 人血浆 lansoprazole high performance capillary electrophoresis chiral separation human plasma
  • 相关文献

参考文献13

  • 1SHIN J M, MUNSON K, VAGIN O, et al. The gastric HK-ATPase: structure, function, and inhibition [J]. Pflugers Arch-Eur J Physiol, 2009, 457:609-622.
  • 2简文娟,李刚.兰索拉唑注射剂治疗上消化道大出血的疗效观察[J].西北药学杂志,2008,23(5):320-321. 被引量:6
  • 3MIURA M, TADA H, YASUI F N, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes[J]. Eur J Clin Pharmacol, 2004, 60:623-628.
  • 4MIURA M. Enantioselective disposition of lansoprazole and rabeprazole in human plasma [J].Yakugaku Zasshi, 2006, 126(6):395-402.
  • 5CIRILLI R, FERRETTI R, GALLINELLA B, et al. Development and validation of an enantioselective and chemoselective HPLC method using a Chiralpak IA column to simultaneously quantify (R)-(+)- and (S)-(−)-lansoprazole enantiomers and related impurities [J].J Pharmaceut Biomed,2009,50:9-14.
  • 6BARREIRO J C, VANZOLINI K L, CASS Q B. Direct injection of native aqueous matrices by achiral–chiral chromatography iontrap mass spectrometry for simultaneous quantification of pantoprazole and lansoprazole enantiomers fractions [J]. J Chromatogr A, 2011,1218:2865-2870.
  • 7关瑾,杨晶,石爽,阎峰,李发美.磺丁基醚-β-环糊精手性流动相添加剂法分离兰索拉唑对映体[J].分析试验室,2009,28(2):91-93. 被引量:12
  • 8TORIBIO L, DEL NOZAL M J, BERNAL J L, et al. Comparative study of the enantioselective separation of severalantiulcer drugs by high-performance liquid chromatography and supercritical fluid chromatography [J]. J Chromatogra A, 2005, 1091:118-123.
  • 9EBERLE D, HUMMEL R P, KUHN R. Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis [J].J Chromatogr A, 1997,759:185-192.
  • 10NEVADO J J B, PENALVO G C, SANCHEZ J C J, et al. Optimisation and validation of a new CE method for the determination of lansoprazole enantiomers in pharmaceuticals [J]. Electrophoresis, 2009, 30:2940-2946.

二级参考文献43

共引文献28

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部